Myocardial perfusion imaging with technetium-99m-labeled agents.
Myocardial perfusion imaging with technetium-99m-labeled agents.
复制标题
使用锝-99m 标记试剂进行心肌灌注成像。
DOI：
10.1016/s0002-9149(05)80005-0
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Berman,DS
中科院分区：
文献类型：
--
作者：
Maddahi,J;Kiat,H;Berman,DS
铊-201（201 Tl）作为心肌灌注成像的单光子发射剂，由于其低能量光子和长半衰期，因此不是最佳选择。为了克服这些局限性，两种新的心肌灌注显像剂标记的锝-99m（99 mTc）已被开发。它们是Tc-sestamibi和Tc-teboroxime。两种示踪剂心肌灌注的临床试验显示，结果与201 Tl检测冠状动脉疾病的结果相似。迄今为止的结果表明，Tc-sestamibi准确地检测和定位心肌梗死，并可以准确地评估左心室和右心室射血分数的首过技术。此外，研究表明，静息-应激研究可以在同一天进行，Tc-sestamibi可用于评估溶栓治疗的结果。Tc-替硼肟具有优异的心肌示踪剂摄取特性，但从心肌中清除非常迅速。这些特点使Tc-teboroxime非常适合快速系列研究。这些新的锝心肌灌注剂刚刚成为可用于常规临床使用，并有可能取代201铊在其许多临床应用。
Thallium-201 (201Tl) is suboptimal as a single-photon emitting agent for myocardial perfusion imaging, in view of its low-energy photons and long half-life. To circumvent these limitations, two new myocardial perfusion imaging agents labeled with technetium-99m (99mTc) have been developed. They are Tc-sestamibi and Tc-teboroxime. Clinical trials of myocardial perfusion with both tracers have shown results similar to those obtained with201Tl for detection of coronary artery disease. Results to date indicate that Tc-sestamibi accurately detects and locates myocardial infarction and can accurately assess both left and right ventricular ejection fractions by the first-pass technique. In addition, research has shown that rest-stress studies can be performed on the same day and that Tc-sestamibi can be used to assess the results of thrombolytic therapy. Tc-teboroxime has excellent myocardial tracer uptake characteristics but is cleared very rapidly from the myocardium. These features make Tc-teboroxime well suited to rapid serial studies. These new technetium myocardial perfusion agents have just become available for routine clinical use and are likely to replace201Tl in many of its clinical applications.